Borna disease virus (BDV)-induced model of autism: application to vaccine safety test design.
Carbone
K M
KM
Dept of Psychiatry, The Johns Hopkins University School of Medicine, Ross 618, 720 Rutland Avenue, Baltimore, MD 21205, USA. carbonek@cber.fda.gov
Rubin
S A
SA
Pletnikov
M
M
D000818:Animals; D001321:Autistic Disorder / Q000209:etiology*; D001522:Behavior, Animal; D001890:Borna Disease / Q000150:complications / Q000473:pathology* / Q000523:psychology; D001891:Borna disease virus / Q000472:pathogenicity*; D001925:Brain Damage, Chronic / Q000209:etiology; D002490:Central Nervous System / Q000473:pathology*; D002531:Cerebellum / Q000473:pathology; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D006801:Humans; D006849:Hydrocephalus / Q000209:etiology; D008032:Limbic System / Q000473:pathology; D009107:Mumps / Q000150:complications; D009108:Mumps Vaccine / Q000009:adverse effects*; D009109:Mumps virus / Q000472:pathogenicity; D009422:Nervous System Diseases / Q000209:etiology* / Q000473:pathology; D018377:Neurotransmitter Agents / Q000378:metabolism; D051381:Rats; D012449:Safety; D014613:Vaccines, Attenuated / Q000009:adverse effects
D016207:Cytokines; D009108:Mumps Vaccine; D018377:Neurotransmitter Agents; D014613:Vaccines, Attenuated